FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA
Clinical trials for FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New chemo schedule tested to improve ovarian cancer outcomes
Disease control OngoingThis study tested whether giving the chemotherapy drug paclitaxel weekly works better than the standard every-3-weeks schedule for people with advanced ovarian, peritoneal, or fallopian tube cancer. All participants also received carboplatin, and some received the targeted drug b…
Matched conditions: FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:38 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 participants will receive o…
Matched conditions: FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:36 UTC
-
Measles virus reprogrammed to attack ovarian cancer shows promise in early trial
Disease control OngoingThis study tests a new treatment for ovarian cancer that has come back after standard therapy. It uses stem cells loaded with a modified measles virus to deliver cancer-killing effects directly into the abdomen. The trial involves 34 participants and aims to find the safest dose …
Matched conditions: FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 04:34 UTC
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
New hope for recurrent ovarian cancer: drug combo extends life?
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…
Matched conditions: FALLOPIAN TUBE MUCINOUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC